Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis

a technology of benzene sulfonic acid and 2,5-dihydroxybenzene sulfonic acid, which is applied in the direction of biocide, drug composition, immunological disorders, etc., can solve the problems of no cure for psoriasis, poor treatment effect of patients with advanced solid tumors, etc., and achieve the effect of improving the efficacy of chemotherapy

Inactive Publication Date: 2007-06-28
ACTION MEDICINES SL
View PDF23 Cites 59 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] The invention describes methods for (a) treating skin cancer; (b) treating cancer of an organ; (c) treating leukemia; and (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy in a patient in need thereof comprising administering to the patient an effective amount of at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof. The methods can optionally further comprise the administration of at least one therapeutic agent, such as, for example, chemotherapeutic agents, steroids, retinoids, antimicrobial compounds, antioxidants

Problems solved by technology

The overall five-year survival approximates fifty percent for all patients, and the prognosis rema

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
  • Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
  • Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis

Examples

Experimental program
Comparison scheme
Effect test

example 1

2,5-Dihydroxybenzene Sulfonic Acid Potentiates Chemotherapy

[0135] C6 cells cultured in vitro under the same conditions as described in PCT Application No. 2005 / 077352. 1. 1×103 cells per well were cultured in 24-well plates. Three types of treatment were conducted: a) 24 hours after seeding, the cells were separately treated with each of the following medicines; cisplatin (5 μg / ml), vincristine (0.1 μg / ml), paclitaxel (5 μg / ml) and 5-fluorouracil (100 g / ml); b) 24 hours after seeding, the cells were treated with a combination of 2,5-dihydroxybenzene sulfonic acid (100 μM) and each one of the following agents; cisplatin (5 μg / ml) vincristine (0.1 μg / ml), paclitaxel (5 μg / ml) and 5-fluorouracil (100 μg / ml); c) at the time of seeding (Day 0), the cells were pre-treated with 2,5-dihydroxybenzene sulfonic acid (100 μM). The next day the cultures were also treated with each one of the following agents: cisplatin (5 μg / ml) vincristine (0.1 μg / ml), paclitaxel (5 μg / ml) and 5-fluorouracil (...

example 2

2,5-Dihydroxybenzene Sulfonate Increases the Chemo Sensitivity in Rat C6 Glioma Cells

[0138] Cultures of rat glioma C6 cells were grown as described in Cuevas P et al. Neurol. Res., 27: 797-800 (2005). Briefly, cells were grown as adherent cells in Dulbecco modified Eagle medium supplemented with 1% (v / v) fatal bovine serum, 10 μg / ml streptomycin and 10 units / ml penicillin (DMEM). Tumour cells were set up in 24-well cell culture plates, at a density of 10,000 cells per well and incubated at 37° C. in a humidified chamber with 5% CO2. Cells were either treated with 2,5-dihydroxybenzene sulfonate (100 μM in DMEM) or with DMEM (controls). Eighty hours after the addition of 2,5-dihydroxybenzene sulfonate, the cells were either treated or not treated with the cytostatic agents, cisplatin (5 μg / ml in DMEM), vincristine (0.5 μg / ml in DMEM), paclitaxel (5 μg / ml in DMEM), 5-fluorouracil (100 μg / ml in DMEM) and irinotecan (CPT-11; 0.1 μg / ml in DMEM). After an additional two days the prolifera...

example 3

2,5-Dihydroxybenzene Sulfonate Increases the Efficacy of Irinotecan (CPT-11) in Rat Glioma

[0140] Cultures of rat glioma C6 cells were grown as described in Cuevas P et al. Neurol. Res., 27: 797-800 (2005). Confluent C6 cells cultured in 75 cm2 flasks were detached and implanted into the left frontal lobe of anaesthetized rats using a stereotactic device. The implantation of the 106 glioma cells was accomplished by means of a Hamilton syringe coupled to a glass pipette (40-60 μm in diameter) through a small orifice performed in the cranium by a stainless steel needle. FIG. 3, panels A, B and C shows the magnetic resonance image of the rat brain two weeks after implantation. Ten days after the existence of a tumour was confirmed, rats were randomly assigned to receive or not receive 2,5-dihydroxybenzene sulfonate (200 mg / kg / day in saline; i.p) throughout the period of observation. Two days after starting the treatment with 2,5-dihydroxybenzene sulfonate, the rats were treated with ir...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Therapeuticaaaaaaaaaa
Pharmaceutically acceptableaaaaaaaaaa
Antimicrobial propertiesaaaaaaaaaa
Login to view more

Abstract

The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compounds or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate.

Description

RELATED APPLICATIONS [0001] This application is a continuation-in-part of U.S. application Ser. No. 10 / 588,166 filed Aug. 2, 2006, which claims priority under 35 USC §120 to PCT / ES2005 / 070017 filed Feb. 16, 2005; which claims priority under 35 USC §119 to ES Application No. P200400371, filed Feb. 17, 2004; the disclosures of which is incorporated by reference herein in its entirety.FIELD OF THE INVENTION [0002] The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and / or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at le...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/185A61K31/60A61K31/59A61K31/56
CPCA61K31/185A61K31/56A61K31/59A61K31/095A61K45/06C07C309/29A61K31/60A61P17/00A61P17/06A61P17/18A61P29/00A61P31/00A61P35/00A61P35/02A61P37/02A61K9/0014
Inventor CUEVAS SANCHEZ, PEDROROMERO GARRIDO, ANTONIOGIMENEZ GALLEGO, GUILLERMOVALVERDE LOPEZ, SERAFINLOZANO PUERTO, ROSA MARIA
Owner ACTION MEDICINES SL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap